ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2013
Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
151 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Nutritional Risk Screening Tools for Older Adults with COVID-19: A Systematic Review.Nutrients · 2020Pooled it
- Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.Diabetes, obesity & metabolism · 2026Trial
- Efficacy and Sustainability of Diabetes-Specific Meal Replacement on Obese and Overweight Type-2 Diabetes Mellitus Patients: Study Approaches for a Randomised Controlled Trial and Impact of COVID-19 on Trial Progress.International journal of environmental research and public health · 2022Trial
- Effects and Mechanisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension.Medical science monitor : international medical journal of experimental and clinical research · 2020Trial
- Evaluating differences in the clinical impact of a free online weight loss programme, a resource-intensive commercial weight loss programme and an active control condition: a parallel randomised controlled trial.BMC public health · 2019Trial
- The Interaction of a Diabetes Gene Risk Score With 3 Different Antihypertensive Medications for Incident Glucose-level Elevation.American journal of hypertension · 2019Trial
- Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.Journal of clinical hypertension (Greenwich, Conn.) · 2018Trial
- Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial.Scientific reports · 2018Trial
- Psoriasis risk in patients with diabetic retinopathy: A nationwide population-based study.Scientific reports · 2018Trial
- Data, Process, and Data-Driven Representations of Digital Twins in Diabetes: Scoping Review.JMIR diabetes · 2026Review
- Glucagon-Like Peptide-1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications.Pharmacology research & perspectives · 2026Review
- Early Postural Instability with History of COVID-19 Influence Related to Diabetes: An Exploratory Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Prevalence of diabetes/prediabetes and their associated risk factors among adults with hypertension from iran: a nationwide study.Scientific reports · 2026Article
- A realist review to understand the complexity of effective management of type 2 diabetes and hypertension.Public health reviews · 2026Review
- Metabolic dysfunction-associated steatotic liver disease in individuals with type 2 diabetes mellitus and diabetic foot ulcers: prevalence and associated factors.Journal of diabetes and metabolic disorders · 2025Article
- Article
- PET Imaging of Diabetes-Induced Alterations in Metabolism and Immune Activation.Molecular imaging and biology · 2025Article
- Time Trends of Body Mass Index and its Impact on Glycemic Control Among Finnish Patients with Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Magnitude and determinants of isolated systolic hypertension among type 2 diabetes patients in selected referral hospitals in Amhara Region, Ethiopia.Scientific reports · 2025Article
91 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension and obesity are known to contribute, directly or indirectly, to the development of long-term complications of type 2 diabetes mellitus (T2DM). Knowing the prevalence of these comorbidities is important for determining the size of the population that may benefit from strategies that reduce blood pressure and weight while controlling blood glucose.
methodsIn this systematic literature review, electronic searches of PubMed, Embase, and the Cochrane Library were conducted to identify observational studies of hypertension and/or obesity prevalence in patients with T2DM throughout the world. The searches were limited to studies reported in English from January 1, 2001 to February 16, 2012.
resultsFrom a total of 2,688 studies, 92 observational studies provided prevalence rates for hypertension and/or obesity specifically in adults with T2DM. Fifteen studies of specific subtypes of hypertension or subpopulations with T2DM were subsequently excluded, leaving 78 studies (in 77 articles) for inclusion in this article. Of these, 61studies reported hypertension prevalence, 44 reported obesity prevalence, and 12 reported the prevalence of hypertension with obesity. Most studies had a low risk of bias regarding diagnosis of T2DM (70/78), hypertension (59/69), or obesity (45/47). The continental regions with the most observational studies of hypertension or obesity prevalence were Europe (n = 30) and Asia (n = 26). Hypertension rates typically were high in all regions; most studies presented rates above 50%, and many presented rates above 75%. Obesity rates exceeded 30% in 38 of 44 studies and 50% in 14 of 44 studies, especially those assessing central obesity (based on waist circumference). Among obese adults, hypertension rates were at or above 70% in Asia and above 80% in Europe; rates were lower in North and South America but still above 30%.
conclusionAround the world, hypertension and obesity, separately or together, are common comorbidities in adults with T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.